 |
17 Diseases |  |
2 Trials |
|
2 Trials |  |
101 News |  |
| «12 |
- | Imfinzi (durvalumab) / AstraZeneca
Enrollment open, Trial initiation date, Trial primary completion date, Metastases: Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma (clinicaltrials.gov) - Apr 7, 2016
P1/2, N=26, Recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: May 2017 --> Aug 2017
- || AZD5069 / AstraZeneca
Trial primary completion date: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (clinicaltrials.gov) - Mar 1, 2016
P2, N=1147, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Initiation date: Dec 2015 --> Mar 2016 | Trial primary completion date: May 2017 --> Aug 2017 Trial primary completion date: Mar 2014 --> Aug 2014
- || Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Dec 11, 2015
P1/2, N=147, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Mar 2014 --> Aug 2014 Trial primary completion date: May 2017 --> Sep 2017
- | Imfinzi (durvalumab) / AstraZeneca
New P1/2 trial, Metastases: Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma (clinicaltrials.gov) - Oct 22, 2015
P1/2, N=26, Not yet recruiting, Sponsor: AstraZeneca
- || Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Oct 1, 2015
P1/2, N=147, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: May 2017 --> Sep 2017 Trial primary completion date: Dec 2016 --> May 2017
- |||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
Enrollment open, Trial primary completion date, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Aug 27, 2015
P1/2, N=147, Recruiting, Sponsor: AstraZeneca
Trial primary completion date: Dec 2016 --> May 2017 Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Dec 2016
- ||||| Imfinzi (durvalumab) / AstraZeneca, danvatirsen (AZD9150) / AstraZeneca, Flamingo Therapeutics, AZD5069 / AstraZeneca
New P1/2 trial, Combination therapy, Monotherapy, PD(L)-1 Biomarker, IO biomarker, Metastases: Study to Assess MEDI4736 With Either AZD9150 or AZD5069 in Advanced Solid Tumors & Relapsed Metastatic Squamous Cell Carcinoma of Head & Neck (clinicaltrials.gov) - Jul 16, 2015
P1/2, N=147, Not yet recruiting, Sponsor: AstraZeneca
- |||| AZD5069 / AstraZeneca
Trial completion: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (clinicaltrials.gov) - Sep 28, 2014
P2, N=1147, Completed, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting | Trial primary completion date: Mar 2018 --> Dec 2016 Active, not recruiting --> Completed
- | AZD5069 / AstraZeneca
Trial completion: Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069 (clinicaltrials.gov) - Sep 19, 2014
P1, N=14, Completed, Sponsor: AstraZeneca
Active, not recruiting --> Completed Recruiting --> Completed
- || AZD5069 / AstraZeneca
Enrollment change: Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069 (clinicaltrials.gov) - Jun 18, 2014
P1, N=84, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=57 --> 84
- ||| AZD5069 / AstraZeneca
Trial completion: Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069 (clinicaltrials.gov) - Jun 17, 2014
P1, N=57, Completed, Sponsor: AstraZeneca
N=57 --> 84 Recruiting --> Completed
- AZD5069 / AstraZeneca
Enrollment change: Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069 (clinicaltrials.gov) - May 4, 2014
P1, N=36, Completed, Sponsor: AstraZeneca
Recruiting --> Completed N=16 --> 36
- | AZD5069 / AstraZeneca
Trial completion: Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069 (clinicaltrials.gov) - Apr 24, 2014
P1, N=16, Completed, Sponsor: AstraZeneca
N=16 --> 36 Recruiting --> Completed
- AZD5069 / AstraZeneca
Enrollment open: Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069 (clinicaltrials.gov) - Apr 8, 2014
P1, N=8, Recruiting, Sponsor: AstraZeneca
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||| AZD5069 / AstraZeneca
Enrollment change: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (clinicaltrials.gov) - Jan 30, 2014
P2, N=1147, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting N=564 --> 1147
- ||| AZD5069 / AstraZeneca
Enrollment open: Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069 (clinicaltrials.gov) - Nov 26, 2013
P1, N=57, Recruiting, Sponsor: AstraZeneca
N=564 --> 1147 Not yet recruiting --> Recruiting
- | AZD5069 / AstraZeneca
New P1 trial: Study to Investigate Relative Bioavailability of up to Five Different Formulations of AZD5069 (clinicaltrials.gov) - Nov 19, 2013
P1, N=16, Completed, Sponsor: AstraZeneca
- ||| AZD5069 / AstraZeneca
Enrollment closed: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (clinicaltrials.gov) - Oct 30, 2013
P2, N=1147, Active, not recruiting, Sponsor: AstraZeneca
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||| AZD5069 / AstraZeneca
New P1 trial: Study to Investigate Safety, Tolerability and Effect of Multiple Dosing With AZD 4721 and/or With AZD 5069 (clinicaltrials.gov) - Oct 14, 2013
P1, N=57, Recruiting, Sponsor: AstraZeneca
- AZD5069 / AstraZeneca
New P1 trial: Distribution of Neutrophils in Bronchial Mucosal Tissue in Asthma Patients Before and After 4 Weeks Treatment With AZD 5069 (clinicaltrials.gov) - Jun 27, 2013
P1, N=8, Recruiting, Sponsor: AstraZeneca
- | AZD5069 / AstraZeneca
Trial completion: Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally. (clinicaltrials.gov) - Feb 17, 2013
P1, N=15, Completed, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Recruiting --> Completed
- | AZD5069 / AstraZeneca
New P1 trial: Phase I Study to Assess the Effect on Healthy Male Volunteers of Ketoconazole on the Pharmacokinetics of a Single Dose of AZD5069 Administered Orally. (clinicaltrials.gov) - Nov 26, 2012
P1, N=15, Completed, Sponsor: AstraZeneca
- ||||| AZD5069 / AstraZeneca
New P2 trial: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of AZD5069 in Patients With Uncontrolled Persistent Asthma. (clinicaltrials.gov) - Oct 9, 2012
P2, N=1147, Active, not recruiting, Sponsor: AstraZeneca
- | AZD5069 / AstraZeneca
Trial completion: AZD5069 Neutrophil Function Study (clinicaltrials.gov) - Aug 8, 2012
P1, N=30, Completed, Sponsor: AstraZeneca
Recruiting --> Completed Suspended --> Completed
- ||| AZD5069 / AstraZeneca
Enrollment change: STRATUS: Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (clinicaltrials.gov) - Mar 11, 2012
P2, N=83, Completed, Sponsor: AstraZeneca
Suspended --> Completed N=60 --> 83
- |||| AZD5069 / AstraZeneca
Trial completion: STRATUS: Evaluation of the Effect of AZD5069 in Patients With Bronchiectasis (clinicaltrials.gov) - Mar 11, 2012
P2, N=83, Completed, Sponsor: AstraZeneca
N=60 --> 83 Recruiting --> Completed
- | AZD5069 / AstraZeneca
New P1 trial: AZD5069 Neutrophil Function Study (clinicaltrials.gov) - Nov 27, 2011
P1, N=30, Completed, Sponsor: AstraZeneca